Department of Physiology & Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA.
Department of Pharmacology & Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA.
Psychopharmacology (Berl). 2022 Jun;239(6):1665-1677. doi: 10.1007/s00213-022-06092-x. Epub 2022 Mar 2.
Clinical studies suggest that psychedelics exert robust therapeutic benefits in a number of psychiatric conditions including substance use disorder. Preclinical studies focused on safety and efficacy of these compounds are necessary to determine the full range of psychedelics' effects.
The present study explores the behavioral pharmacology of structurally distinct psychedelics in paradigms associated with serotonin 2A receptor (5-HTR) activation and behavioral disruption in two rodent models. Utilizing the selective 5-HTR antagonist volinanserin, we aimed to provide further pharmacological assessment of psychedelic effects in rodents.
We compared volinanserin (0.0001-0.1 mg/kg) antagonism of the phenethylamine 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI, 1.0 mg/kg) and the ergoline lysergic acid diethylamide (LSD, 0.32 mg/kg) in preclinical assays predictive of hallucinations (head-twitch response or HTR in mice) and behavioral disruption (intracranial self-stimulation or ICSS in rats). Volinanserin antagonism of the phenethylamine mescaline, the tryptamine psilocybin, and the k-opioid receptor agonist salvinorin A was also evaluated in the rat ICSS assay.
Volinanserin had similar potency, effectiveness, and time-course to attenuate DOI-induced HTR in mice and ICSS depression in rats. Volinanserin completely blocked LSD-induced HTR in mice, but not LSD-induced ICSS depression in rats. Volinanserin also reversed ICSS depression by mescaline, but it was only partially effective to reduce the effects of psilocybin, and it exacerbated ICSS depression by salvinorin A.
Although hallucination-related HTR behavior induced by phenethylamine, ergoline, and tryptamine psychedelics appears to be 5-HTR-mediated, the receptor(s) responsible for behavioral disruptive effects may differ among these three structural classes.
临床研究表明,迷幻剂在包括药物使用障碍在内的多种精神疾病中具有强大的治疗益处。需要进行这些化合物的安全性和疗效的临床前研究,以确定迷幻剂作用的全部范围。
本研究在与 5-羟色胺 2A 受体(5-HTR)激活和两种啮齿动物模型中的行为障碍相关的范式中探索结构不同的迷幻剂的行为药理学。利用选择性 5-HTR 拮抗剂伏林司他,我们旨在进一步评估迷幻剂在啮齿动物中的作用。
我们比较了伏林司他(0.0001-0.1mg/kg)对苯乙胺 1-(2,5-二甲氧基-4-碘苯基)-2-氨基丙烷(DOI,1.0mg/kg)和麦角酰二乙胺(LSD,0.32mg/kg)的拮抗作用,这两种药物在预测幻觉(摇头反应或 HTR 在小鼠中)和行为障碍(颅内自我刺激或 ICSS 在大鼠中)的临床前试验中。伏林司他对苯乙胺麦斯卡林、色胺裸盖菇素和 k-阿片受体激动剂萨洛宾林 A 的拮抗作用也在大鼠 ICSS 试验中进行了评估。
伏林司他对 DOI 诱导的 HTR 在小鼠中的作用具有相似的效力、有效性和时程,以及对大鼠 ICSS 抑郁的作用。伏林司他完全阻断了 LSD 诱导的 HTR 在小鼠中的作用,但不能阻断 LSD 诱导的大鼠 ICSS 抑郁。伏林司他还逆转了麦斯卡林引起的 ICSS 抑郁,但对减少裸盖菇素的作用只有部分有效,并加剧了萨洛宾林 A 引起的 ICSS 抑郁。
尽管苯乙胺、麦角碱和色胺迷幻剂引起的与幻觉相关的 HTR 行为似乎是 5-HTR 介导的,但这些三种结构类别之间引起行为障碍的受体可能不同。